Novartis subcutaneous mAb for MS, Incyte and Karyopharm oral cancer therapies backed by CHMP

Among the therapies to receive a positive opinion from EMA’s CHMP in January were drugs from Novartis, Incyte and Karyopharm that have convenient routes of administration. 

The agency backed Kesimpta ofatumumab, an auto-injectable anti-CD20 mAb from  Novartis AG (NYSE:NVS; SIX:NOVN), to treat active relapsing forms of multiple sclerosis. The subcutaneous route of administration for Kesimpta, which FDA approved in August, could give it an edge over other CD20-targeting mAbs that need to be given IV at infusion centers, including Ocrevus ocrelizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY)...